S. Margaret Paik to Everolimus
This is a "connection" page, showing publications S. Margaret Paik has written about Everolimus.
Connection Strength
0.210
-
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer. J Clin Oncol. 2024 Sep 01; 42(25):3012-3021.
Score: 0.210